We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
http://www.clear-uk.org/fast-developing-news-cbd-medicinal-cannabis/
Yes looking like a down day today !
think we may have hit the top on nasdaq...
GWP Support from Leerink yesterday evening: PT = $162GWP Leerink resumed coverage on GW Pharmaceuticals PLC (NASDAQ: GWPH) in anticipation of FDA approval for Epidiolex. Analyst Paul Matteis expressed an Outperform Rating, and set the firm’s price target at $162. Matteis primarily cited the FDA’s pending approval of Epidiolex, and the firm’s confidence in the drug as the reason for his bullish resumption of coverage. Related Link: Exclusive: GW Pharmaceuticals Talks Epidiolex, Raising Capital & Growing Its Sales Force The analyst stated a 90 percent probability for FDA approval following three positive Phase III trials. Looking forward, Matteis is also optimistic concerning a global launch for Epidiolex, which is currently being administered to more than 1,000 children affected by Dravet Syndrome, Lennox Gastaut Syndrome and refractory seizures. The stock traded recently at $132.80 after opening at $134.81. Latest Ratings for GWPH Date Firm Action From To Oct 2016 Leerink Swann Assumes Outperform Sep 2016 Morgan Stanley Maintains Overweight Sep 2016 Cantor Fitzgerald Maintains Buy
Gwph finished slightly up , good sign
I think it will keep rising, maybe not constantly. I expect it to hit £10 by January. If GW get FDA and another positive result then the £10 + is easily attainable.
kicking and screaming like i said :) you dont want to risk it, but you dont want to miss out either ....
Yes doin well on this one got a fair few grand in now , dont want a massive drop , gonna set another stop loss but it caught me out a bit last week
the takeover rumours were 'priced' at approx $165 'officially'...but do you believe the rumour? if you do then we have a bit more forever to go yet. imo if the markets stay bullish then we can still go higher, GW has a knack of going higher than people believe, it drags some in kicking and screaming...if they sold to early. im not seeing the signs that say we have hit the top...yet.
Forever , there must be people who know what price the takeover rumours were set at , cos theres no results or news expected now is there , any ideas
Ha ha by jove uve got it ! Lol
blimey :(
going up against the authorities is not always clever... https://www.theguardian.com/society/2016/sep/28/charlo-greene-alaska-cannabis-club-reporter-marijuana?CMP=share_btn_fb
freddie . . . divide by 12, then again divide by exchange rate (1.27- 1.3)
is Hilary finished? http://www.express.co.uk/news/world/717196/Hillary-is-done-warning-Julian-Assange-WikiLeaks-major-announcement
From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term. Looking for breakout at 870.97 with a short term target of 1017.29. http://uk.stoxline.com/q_uk.php?s=gwp
So with a takeover maybe 12quid ?
its just over 10 quid..;)
Looking very good 1.60 on gwph would give us wat roughly in pounds , and i know u have told me before king lol
nice :)
As a reminder, GW Pharma maintains a September fiscal year end. With these changes, our GWPH PT increases to $160 per share.
Further to excellent research on GWP these last few days I got in touch with my broker and asked if they had a broker note on last weeks trial results, they said indeed we have and its a cracker............they say Morgan Stanley are a Giant Bull on the stock. <b><u>Morgan Stanley</u></b> <b><i>Second LGS trial succeeds, with Epidiolex showing similar efficacy to the first LGS trial. Yesterday, GW Pharma reported results from the second Phase 3 study of Epidiolex in Lennox-Gastaut Syndrome (LGS). The patients enrolled in the trial had highly refractory disease, taking an average of three anti-epileptic drugs (AEDs) concurrently, and having failed 7 previously. These patients had a baseline seizure frequency of 85/month. During the treatment period, patients taking Epidiolex 20mg/kg per day (n=76) on top of their current therapy achieved a median reduction in monthly drop seizures of 42% compared with a reduction of 17% in patients taking placebo (n=76), resulting in a 25% statistically significant treatment effect (p=0.0047). Patients taking Epidiolex 10mg/kg per day (n=73) achieved a median reduction in monthly drop seizures of 37% compared with a reduction of 17% in patients taking placebo, a statistically significant treatment effect of 20% (p=0.0016). As a reminder, Epidiolex demonstrated a reduction in drop seizures of 44% vs. 22% for placebo in the first Phase 3 LGS study reported in June. Safety for Epidiolex appears consistent with prior trials and the ongoing expanded access program. AEs were recorded in 84% of patients treated at 10mg/kg (89% of which were mild/moderate), 94% of patients in the 20mg/kg group (88% mild/moderate), and 72% of placebo patients. The most common (greater than 10%) AEs across dose groups included somnolence, decreased appetite, diarrhea, and upper respiratory tract infection. Additionally, in the 20mg/kg group there were common reports of pyrexia, vomiting and nasopharyngitis. One potential concern is the status epilepticus experienced by at least 10% of patients in the 10mg/kg group. Although no cases of status epilepticus were deemed treatment related, we continue to monitor these developments. SAEs were found in 13 patients in the 10mg/kg group (2 treatment related), 13 patients in the 20mg/kg group (5 treatment related) and 8 patients receiving placebo. There was one discontinuation due to AEs in the 10mg/kg group, 6 in the 20mg/kg group and one in placebo. No deaths occurred during the study, and 99% of completers opted into an open label extension trial. Updating our model to reflect incremental de-risking; increasing our probability of success for Epidiolex to 85% in Dravet and LGS, and our PT to $160. Given the positive data from the second Phase 3 study in LGS, we have increased our probability of success (POS) for Epidiolex in both LGS and Dravet Syndrome to 85%, increased our POS in tuberous sclerosis complex (TSC) to 65
yep reading again it does seem as though he's talking about some offering from GW . . . apologies !
no, im pretty sure he was talking about GWP, but which drug.....
http://scibilitymedia.com/cara-therapeutics-inc-nasdaqcara-continues-volume-backed-uptrend/